<\/p>\n\n\n\n Global medical wearables market: \u20ac18\u201320B (2025) \u2192 \u20ac57B+ by 2030 (CAGR ~17%).<\/p>\n\n\n\n \u2022 Healthcare: \u20ac1.3\u20137B<\/strong> \u2022 B2B2C: Device (\u20ac200\u2013400) + subscription (\u20ac15\u201330\/mo) + brokerage fees via EuDiPPA. \u2022 Unique differentiator: Retraction strategy eliminates risk exposure \u2014 first in class for sovereign, patient-first edge-AI. \u2022 Seed\/bridge funding: \u20ac2\u20135M<\/strong> equity\/debt (post-grant traction). Lean structure with part-time experts<\/p>\n\n\n\n \u2022 Johannes Petrus Maria (John) Wubbe \u2013 President & Founder (vision\/strategy). Download the Investor Deck or contact us to discuss: Join the Next Phase of DocSWISS-AI DocSWISS-AI \u2014 our radiation-tolerant edge-AI vital signs patch at TRL 4 \u2014 is lab-validated and ready for pilots. As the first CRO with space-validated evidence targeting a fast-track EMA pathway, it delivers the decision cockpit: real-time predictive alerts (target \u226595% accuracy) + unique retraction strategy to eliminate ongoing risk […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-187","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/doc.swiss\/index.php\/wp-json\/wp\/v2\/pages\/187","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/doc.swiss\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/doc.swiss\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/doc.swiss\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/doc.swiss\/index.php\/wp-json\/wp\/v2\/comments?post=187"}],"version-history":[{"count":14,"href":"https:\/\/doc.swiss\/index.php\/wp-json\/wp\/v2\/pages\/187\/revisions"}],"predecessor-version":[{"id":382,"href":"https:\/\/doc.swiss\/index.php\/wp-json\/wp\/v2\/pages\/187\/revisions\/382"}],"wp:attachment":[{"href":"https:\/\/doc.swiss\/index.php\/wp-json\/wp\/v2\/media?parent=187"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
<\/strong>DocSWISS-AI \u2014 our radiation-tolerant edge-AI vital signs patch at TRL 4 \u2014 is lab-validated and ready for pilots. As the first CRO with space-validated evidence targeting a fast-track EMA pathway, it delivers the decision cockpit: real-time predictive alerts (target \u226595% accuracy) + unique retraction strategy to eliminate ongoing risk (QoL\/performance\/safety impact). This avoids massive follow-up costs from wrong decisions \u2014 unnecessary interventions, liability claims, lost productivity, and even preventable deaths \u2014 while costing clients only ~10% of the avoided expenses. <\/p>\n\n\n\nMarket Opportunity<\/h4>\n\n\n\n
Cross-sector TAM<\/h4>\n\n\n\n
\u2022 Defense & Security: \u20ac4.7B<\/strong>
\u2022 Space: \u20ac1.5\u20131.7B<\/strong>
\u2022 Industrial Safety: \u20ac2\u20135B<\/strong>
\u2022 Aviation & Mass Events: Included in defense\/aviation
\u2022 Financial\/Insurance & Wellness: \u20ac12\u201314B<\/strong><\/p>\n\n\n\n
Business Model & Traction<\/h4>\n\n\n\n
\u2022 Realistic 5-year revenue: \u20ac450\u2013500M<\/strong> (base case).
\u2022 Break-even: Year 2\u20133.
\u2022 Exit target: Acquisition by medtech\/defense corporation (2029\u20132032).
\u2022 Current stage: TRL 4 (lab-validated) \u2192 seeking pilots (TRL 5\u20136), grants (EU4Health, Horizon, EIC), and seed\/bridge funding (\u20ac8\u201312M total)<\/strong>.<\/p>\n\n\n\n
Why Invest Now?<\/h4>\n\n\n\n
\u2022 Space-validated fast-track EMA: Dual-use resilience (radiation >100\u2013300 krad) from space analogs \u2192 clinical approval advantage.
\u2022 Lean startup model: All key team members part-time domain experts (high-caliber, low-cost) \u2014 scalable to full-time.
\u2022 Strong foundation: MoU\/NDA signed with EuDiPPA, Digital Health Europe (Partnering 4 Human Health & Performance, Improving Outcomes & Impacts), and Prof. C.J. Schilt (VUB \u2013 grant\/university coordinator).
\u2022 High cross-sector potential: Defense, space, aviation, healthcare, industrial, insurance\/wellness \u2014 \u20ac10B+ combined TAM<\/strong>.<\/p>\n\n\n\n
Investment Ask<\/h4>\n\n\n\n
\u2022 Total 2026\u20132028: \u20ac8\u201312M (70\u201380% grants + equity).
\u2022 Use of funds: Prototype scaling, pilots, EMA dossier, team growth.
\u2022 Exit potential: Medtech\/defense acquisition (2029\u20132032).<\/p>\n\n\n\n
Team & Expertise (brief summary)<\/h4>\n\n\n\n
\u2022 \u2022 Guilherme (Gon\u00e7alo) Monteiro Ferreira \u2013 Market Access & Pharma (EMA\/payer strategy).
\u2022 Erwin Wolff \u2013 CTO (Rust\/ICT stack).
\u2022 Prof. C.J. Schilt \u2013 Grant\/University Coordinator (ethics\/governance).<\/p>\n\n\n\n
Next Steps for Investors<\/h4>\n\n\n\n
\u2022 Valuation & terms.
\u2022 Grant pipeline leverage (EU4Health Jan 2026, Horizon Apr 2026, EIC May 2026).
\u2022 Equity in Swiss AG structure.
Contact
Email: john.wubbe@doc.swiss
Phone: +41 79 946 38 43<\/p>\n","protected":false},"excerpt":{"rendered":"